Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $114.96 in the prior trading day, Transmedics Group Inc (NASDAQ: TMDX) closed at $111.55, down -2.97%. In other words, the price has decreased by -$2.97 from its previous closing price. On the day, 1.01 million shares were traded. TMDX stock price reached its highest trading level at $113.6799 during the session, while it also had its lowest trading level at $109.59.
Ratios:
Our goal is to gain a better understanding of TMDX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 219.18. For the most recent quarter (mrq), Quick Ratio is recorded 9.17 and its Current Ratio is at 9.86. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 06 ’25 when Hassanein Waleed H bought 8,400 shares for $118.68 per share. The transaction valued at 996,912 led to the insider holds 477,759 shares of the business.
Hassanein Waleed H bought 8,475 shares of TMDX for $985,209 on Aug 07 ’25. The President & CEO now owns 486,234 shares after completing the transaction at $116.25 per share. On Aug 04 ’25, another insider, Basile Edward M, who serves as the Director of the company, sold 4,143 shares for $125.51 each. As a result, the insider received 519,988 and left with 2,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 3802784256 and an Enterprise Value of 3921026304. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 57.68, and their Forward P/E ratio for the next fiscal year is 40.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.16 while its Price-to-Book (P/B) ratio in mrq is 11.94. Its current Enterprise Value per Revenue stands at 7.38 whereas that against EBITDA is 39.092.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.17, which has changed by -0.26116043 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $170.43, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is -6.97%, while the 200-Day Moving Average is calculated to be 19.87%.
Shares Statistics:
The stock has traded on average 1.00M shares per day over the past 3-months and 768960 shares per day over the last 10 days, according to various share statistics. A total of 34.04M shares are outstanding, with a floating share count of 32.94M. Insiders hold about 3.36% of the company’s shares, while institutions hold 109.06% stake in the company. Shares short for TMDX as of 1755216000 were 7841719 with a Short Ratio of 7.80, compared to 1752537600 on 7995364. Therefore, it implies a Short% of Shares Outstanding of 7841719 and a Short% of Float of 39.519999999999996.
Earnings Estimates
The current rating of Transmedics Group Inc (TMDX) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.4, with high estimates of $0.47 and low estimates of $0.29.
Analysts are recommending an EPS of between $2.58 and $1.73 for the fiscal current year, implying an average EPS of $2.21. EPS for the following year is $2.61, with 5.0 analysts recommending between $3.25 and $2.2.
Revenue Estimates
7 analysts predict $144.48M in revenue for the current quarter. It ranges from a high estimate of $147.57M to a low estimate of $140.5M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $108.76MFor the next quarter, 7 analysts are estimating revenue of $155.47M. There is a high estimate of $159.8M for the next quarter, whereas the lowest estimate is $148.61M.
A total of 8 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $605M, while the lowest revenue estimate was $582.2M, resulting in an average revenue estimate of $599.03M. In the same quarter a year ago, actual revenue was $441.54MBased on 8 analysts’ estimates, the company’s revenue will be $715.43M in the next fiscal year. The high estimate is $730M and the low estimate is $687.4M.
